Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28171931 | 0.83 | HPGD (0.51) | NPSR1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL28080962 | 0.83 | MEN1 (0.51) | NPSR1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL27564194 | 0.76 | NR4A2 (0.46) | NPSR1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL11494832 | 0.76 | NPSR1 (0.57) | NPSR1ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL2594529 | 0.75 | NPSR1 (1.00) | NPSR1ESR1ESR2ALDH1A1MEN1 | |
| SCHEMBL3929385 | 0.72 | ESR1 (0.63) | NPSR1ESR1ESR2ALDH1A1MEN1 | |
| Carbazole SCHEMBL29105374 | 0.72 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| Carbazole SCHEMBL31681675 | 0.72 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AHPGDKDM4E | |
| SCHEMBL17559719 | 0.72 | MEN1 (0.65) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL9285018 | 0.70 | ESR1 (0.42) | ESR1ESR2ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884825-A | Method for synthesizing indole-3-phosphonate | 南京林业大学 | 2016-08-24 | — | — | CN | disclosed |
| EP-2078029-B1 | ENANTIOMERICALLY PURE PHOSPHOINDOLE AS HIV INHIBITOR | IDENIX PHARMACEUTICALS INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8486991-B2 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8470870-B2 | Solid forms of an anti-HIV phosphoindole compound | IDENIX PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-7960428-B2 | (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110039803-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX PHARMACEUTICALS, INC. | 2011-02-17 | — | — | US | disclosed |
| EP-2276771-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009124175-A1 | FORMULATIONS COMPRISING A PHOSPHOINDOLE COMPOUND AND ONE OR MORE SECOND ACTIVE AGENTS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009120914-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| EP-2078029-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008042240-A9 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008042240-A2 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257129-A1 | ENANTIOMERICALLY PURE PHOSPHOINDOLES AS HIV INHIBITORS | DUSP3, PNP, PPP5C | NPSR1 4070/4885ESR1 3562/4885ESR2 4099/4885 |
| US-20110039803-A1 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND | PSPH, PPP5C, PPIP5K2 | NPSR1 3372/4885ESR1 2716/4885ESR2 3311/4885 |
| US-20080213217-A1 | Enantiomerically pure phosphoindoles as HIV inhibitors | DUSP3, PNP, PPP5C | NPSR1 4070/4885ESR1 3562/4885ESR2 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.